Are you Dr. Fontana?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 56 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4100 John R Hwcrc 4th Fl
Karmanos Cancer Center
Detroit, MI 48201Phone+1 800-527-6266Fax+1 313-576-8767- Is this information wrong?
Summary
- Dr. Joseph Fontana, MD is an oncologist in Detroit, Michigan. He is currently licensed to practice medicine in Michigan and Maryland. He is affiliated with Karmanos Cancer Center, DMC Harper University Hospital, and John D. Dingell Department of Veterans Affairs Medical Center.
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1975 - 1976
- Perelman School of Medicine at the University of PennsylvaniaClass of 1975
Certifications & Licensure
- MI State Medical License 1998 - 2023
- MD State Medical License 1987 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2011 Oct 01
- Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
- LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Publications & Presentations
PubMed
- 3 citationsPhase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.Ulka N Vaishampayan, Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson, Brenda Dickow, Dana Schalk, Amy Schienschang, Sarah Whitaker, Amanda Polend...> ;Clinical Cancer Research. 2023 Jan 4
- 27 citationsClinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Cli...Ulka N. Vaishampayan, Lance K. Heilbrun, Paul Monk, Sheela Tejwani, Guru Sonpavde, Clara Hwang, Daryn Smith, Pallavi Jasti, Kimberlee Dobson, Brenda Dickow, Elisabeth ...> ;JAMA Network Open. 2021 Jan 4
- 19 citationsLongitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophiesMinal Jain, Katherine G. Meilleur, Eunhee Kim, Gina Norato, M. Waite, Leslie Nelson, M. McGuire, Tina Duong, Katherine Keller, Donovan J. Lott, Allan Glanzman, Kristy ...> ;Neurology. 2019 Nov 19
- Join now to see all
Grant Support
- Human Leukemia Growth Inhibition By A Novel RetinoidNational Cancer Institute2004–2008
- Induction Of Apoptosis In Breast CancerNational Cancer Institute1999–2002
- Phase II Clinical Trials Of New Chemopreventive AgentsDivision Of Cancer Prevention And Control1998
- Induction Of Apoptosis In Breast CancerNational Cancer Institute1997–1998
- Retinoid Inhibition Of Breast Cancer GrowthNational Cancer Institute1994–1997
- The Role Of C AMP In Leukemic Cell DifferentiationNational Cancer Institute1985
Professional Memberships
- Member
Hospital Affiliations
- DMC Harper University HospitalDetroit, Michigan
- John D. Dingell Department of Veterans Affairs Medical CenterDetroit, Michigan
- DMC Sinai-Grace HospitalDetroit, Michigan
- Karmanos Cancer CenterDetroit, Michigan